login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

First successful below-the-knee procedures with the Proteus device performed in the USA


Friday, 13 Jul 2012 13:47
Proteus
Proteus

Angioslide, a provider of embolic capture angioplasty solutions, has announced the successful deployment of a 3X100mm Proteus device for treating peripheral artery disease in below-the-knee (BTK) vasculature at Community Hospital in Munster, USA. Accommodating a 0.014” guide-wire, the new device allows physician to perform a PTA revascularisation in BTK vessels while capturing and removing embolic particles. 


“With Proteus having been successfully used to treat lesions in the SFA (superficial femoral artery), I had the opportunity to deploy the device in BTK procedures,” said Prakash Makam, Community Hospital. “It is an effective, easy to use tool that provides an alternative for removal of embolic material, including micro particles, that could compromise downstream vasculature flow and perfusion to the foot. This is especially important when treating high-risk, diabetic and critical limb ischaemia patients.”

Angioslide’s proprietary technology combines the functionality of a balloon angioplasty device with the addition of capture and removal of particles released during intervention. Capture of embolic material is enabled by the inward folding of the balloon through a dedicated handle, which creates a suction effect that pulls embolic material into the cavity. When retrieved through the sheath, Proteus removes the captured material from the body.


“We are excited to provide a solution for capture and removal of embolic debris for below-the-knee intervention, where the clinical consequences of emboli are amplified by small vessel diameter,” said Lihu Avitov, CEO, Angioslide. “The current set of tools available on the market for BTK intervention are suboptimal, and we look forward to meeting this important clinical need. With the successful completion of our first cases in the USA, we will introduce our product to a wider number of centers.”


According to a company release, the Proteus is the first device of its kind to receive FDA clearance for use in lower limbs (the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal, and profunda arteries). The device has also received European CE mark approval for lower limb use and is being marketed in selected regions in Europe.




Add New Comment

Related Items


Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Hybrid techniques for the arch: are they effective and durable?
Monday, 17 Feb 2014
Piergiorgio Cao writes that despite the perioperative mortality risk, the late outcome of endovascular arch repair presents a low rate of aorta-related deaths and reinterventions and acceptable mid-... Hybrid techniques for the arch: are they effective and durable?

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions